Developer docs
API playgroundTry for free, no card

Search company profiles

Massive Bio

Full company profile

uuid00002cj

Namestring
Massive Bio
Legal namestring
Massive Bio Inc.
Websiteurl
massivebio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Massive Bio, Inc. is a privately held, Delaware-incorporated AI company headquartered in Boca Raton, Florida, founded in 2015. It operates SYNERGY-AI, an oncology-focused clinical trial matching platform that processes more than 500 medical data elements per patient across 19,000+ active oncology and hematology trials in 17 markets. The platform serves three primary customer segments — cancer patients and caregivers (free, self-serve access via multilingual website and iOS/Android apps), referring oncologists and clinical staff (TrialRelay enrollment orchestration), and 45 enterprise pharma and CRO customers (TrialRelay, NexusPulse commercial/medical intelligence, and Real World Data products). A network of 400+ patient advocacy organizations and 130+ strategic partners (including the American Cancer Society, TOUCH BBCA, Flatiron Health, Foundation Medicine, OpenAI, Optellum, Oracle Cerner, and BeeKeeperAI) feeds consented patient flow into the matching pipeline.

The company's underlying technology is a neuro-symbolic, three-agent AI architecture grounded in an oncology-specific knowledge graph, which Massive Bio bundles as the Reticulum Nexus operating system alongside discrete modules such as Patient Connect, TrialRelay (powered by TrialRouter AI), NexusPulse, DrArturo AI, Phoebe AI, and Sentinel Agents. Performance is backed by a peer-reviewed prospective study in ESMO Real World Data and Digital Oncology covering 3,804 cancer patients and 157,000+ clinical documents, which demonstrated 4x faster trial matching than conventional methods, and by a >40% reduction in signal-to-action time from NexusPulse deployments. Massive Bio maintains a broad regulatory and compliance posture spanning HIPAA, GDPR, PIPEDA, LGPD, SOC 2, DiMe Seal 2026, CMS Medicare App Library listing, OHRP FWA (FWA00030601), and EMA Clinical Trial Regulation registration.

The business model is multi-stream: sponsor-supported managed services (pharma/CRO-funded concierge, navigation, and last-mile coordination), enterprise SaaS contracts for patient identification and enrollment acceleration, and licensing of de-identified real-world data and analytics to patient assistance programs, labs, and pharmaceutical manufacturers. The patient-facing service is free, so monetization runs entirely through enterprise and sponsor channels. To date, Massive Bio has raised approximately $23.3M in cumulative disclosed funding across multiple rounds through a $16.5M Series B led by Revo Capital in December 2022, and the company remains founder-led by CEO Selin Kurnaz, PhD, Chief Medical AI Officer Arturo Loaiza-Bonilla, MD, MSEd, FACP, and CTO/COO Çağatay M. Çulcuoğlu.

Short descriptiontext

Massive Bio operates an AI-powered oncology clinical trial matching platform serving cancer patients, oncologists, and 45 pharma/CRO sponsors across 17 markets, anchored by its SYNERGY-AI engine and Reticulum Nexus multi-agent ecosystem.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoca Raton, United States
HQ citystring
Boca Raton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial matching, oncology patient recruitment, AI clinical trials, real-world data analytics, patient navigation services
Industry4 codes
PRIMARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAE
Clinical Decision Support & Workflow Integration (EHR/oncology systems)
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
NAICS code3 codes
  • Computer Systems Design and Related Services54151
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Prepackaged Software7372
  • Services-Health Services8000
  • Services-Commercial Physical & Biological Research8731
Product category
Oncology Clinical Trial Matching Platform
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model4 records
1Sponsor-Supported Services
TypeManaged Services
Description

Clinical trial sponsors (pharmaceutical or biotechnology companies) fund concierge, navigation, and last-mile coordination services via payments made directly to Massive Bio. Funding does not affect patient rights, cost of care, or eligibility, and is disclosed transparently in patient-facing consents. Identifiable patient data is not shared with sponsors — only de-identified aggregate study metrics.

massivebio.com
2Enterprise SaaS — Pharma / CRO Patient Identification and Trial Enrollment
TypeSubscription Recurring
Description

B2B contracts with 45 pharma and CRO customers (per company) for patient identification, trial enrollment acceleration, site identification, and Real World Data analytics, including TrialRelay™ enrollment orchestration and NexusPulse™ commercial/medical intelligence.

biospace.com
3De-Identified Real-World Data and Analytics Licensing
TypeLicensing Royalties
Description

Massive Bio uses Non-PII to consult other users and may share, lease, or sell de-identified data and analysis to patient assistance programs, clinical laboratories, cancer screening providers, pharmaceutical manufacturers, and oncologists for improvement of professional services and to educate the public.

massivebio.com
4Patient-Facing Service (Free to Patients)
TypeFreemium
Description

Cancer patients and caregivers receive clinical trial matching, second-opinion reports, and patient navigation at no cost; revenue is captured indirectly through sponsor and enterprise contracts rather than direct patient fees.

businesswire.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Personnel, Technology or R&D
Pricing details2 tiers
1Free patient-facing service
ModelFreemium
Notes

No cost to cancer patients and caregivers; 24-hour personalized report turnaround; multilingual support across 11 languages.

massivebio.com
2Quote-based sponsor / pharma / CRO enterprise services
ModelOther
Notes

Pricing not publicly disclosed; sponsor funds concierge, navigation, and last-mile coordination services paid directly to Massive Bio; no effect on patient cost of care.

massivebio.com
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 of 9 records shown
1SYNERGY-AI
Description

Massive Bio's AI-powered clinical trial matching platform used to match cancer patients with oncology and hematology clinical trials.

aijourn.com
+8 more records
Core offering1 text field

Massive Bio operates an AI-powered oncology clinical trial matching platform (SYNERGY-AI) wrapped in the Reticulum Nexus multi-agent operating system, processing 500+ medical data elements per patient against 19,000+ active oncology and hematology trials across 17 markets and 11 languages to deliver physician-reviewed trial reports within 24 hours. It sells TrialRelay physician-facing enrollment orchestration, NexusPulse real-time AI commercial/medical intelligence, and de-identified Real World Data products to pharmaceutical companies, CROs, health systems, and patient advocacy organizations, while offering free clinical trial matching, navigation, and educational content to cancer patients and caregivers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 4x faster AI-driven trial matching vs. conventional methods, validated across 3,804 cancer patients and 157,000+ clinical documents (peer-reviewed in ESMO Real World Data and Digital Oncology)
+6 more records
Product overview1 text field

Massive Bio offers a single unified AI-powered oncology intelligence platform anchored by its flagship SYNERGY-AI™ clinical trial matching engine, wrapped in the next-generation Reticulum Nexus™ multi-agent operating system that orchestrates the full oncology patient journey. The Reticulum Nexus™ suite integrates discrete modules — Patient Connect™ (patient-facing navigation), TrialRelay™ (physician-facing enrollment orchestration) powered by TrialRouter™ AI, NexusPulse™ (real-time AI signal engine for oncology markets), NexusPulse™ Intelligent Calculators, and AI agents Sentinel Agents™, DrArturo AI™, and Phoebe AI™ — into one real-time system. The platform's neuro-symbolic, three-agent AI architecture is grounded in an oncology-specific knowledge graph and validated across 3,804 patients with four-times-faster matching than conventional methods. Supporting products include mobile apps (Synergy-AI Clinical Trial Finder and Cancer Quiz), an Oracle Cerner EHR-integrated app, complementary services (Clinical Trial Matching, Virtual Tumor Board, Drug Utilization Optimizer (DUO), Real World Data), and the Little Tales for Massive Heroes pediatric storybook.

Product and service7 records
1SYNERGY-AI Clinical Trial Matching Platform
CategoryClinical Trial Matching / Oncology AI Platform
Description

AI-powered clinical trial matching platform that processes 500+ medical data elements per patient against 19,000+ active oncology and hematology trials, delivering personalized physician-reviewed trial reports within 24 hours to cancer patients, oncologists, and sponsors across 17 markets. Validated across 3,804 cancer patients and 157,000+ clinical documents.

2Reticulum Nexus Product Suite
CategoryAI Operating System / Platform
Description

AI-powered multi-agent oncology intelligence ecosystem and operating system for oncology access. Orchestrates patient engagement, medical records, eligibility interpretation, clinical trial pre-screening, physician referral orchestration, biomarker intelligence, site activation, and patient navigation into a single real-time AI-enabled operating layer for patients, physicians, sponsors, and CROs.

3TrialRelay
CategoryEnrollment Orchestration / Physician SaaS
Description

Physician-facing AI-powered enrollment orchestration platform powered by TrialRouter AI that eliminates 'referral black holes' by providing warm handoffs, continuous visibility, and closed-loop accountability for oncology patient referrals across health systems and external institutions. Sold to oncologists, health systems, and pharma/CRO sponsors.

4NexusPulse
CategoryCommercial Intelligence / Real-Time Analytics
Description

Real-time AI signal engine for oncology markets that transforms consented real-world clinical and biomarker data into actionable commercial, medical, and market access intelligence for pharma and CRO customers. Built within the Reticulum Nexus ecosystem.

5Patient Connect
CategoryPatient Navigation / Patient-Facing Platform
Description

Patient-facing trial navigation tool that empowers cancer patients and caregivers to manage and navigate their clinical trial journey anytime, anywhere, all in one place. Free to patients; bundled within the Reticulum Nexus ecosystem.

6Virtual Tumor Board
CategoryClinical Decision Support / Consulting Service
Description

Online service providing remote access to bioinformatics and molecular expertise to support patient presentations at tumor boards for oncologists and care teams.

7Drug Utilization Optimizer (DUO)
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierFlagship Strategic PartnerTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

Strategic collaboration announced June 2026 to connect AI-powered lung cancer detection with clinical trial matching for early-stage NSCLC patients. Optellum's FDA-cleared Lung Cancer Prediction (LCP) AI identifies high-risk patients from CT imaging; de-identified data is processed by Massive Bio's platform to match them with geographically accessible NSCLC clinical trials. Targets the gap where most high-risk patients never reach trials despite early detection raising 5-year survival from 9% to 64%.

Strategic tierCore Technology PartnerTypeTechnology or IntegrationAnnounced on2026-05-30
Description

Collaboration enabling privacy-preserving AI-powered clinical trial matching in oncology through encrypted computing, allowing AI models to run on sensitive patient data without exposing it.

Strategic tierCore Strategic PartnerTypeGTM or Marketing PartnerAnnounced on2026-05-29
Description

Embeds Massive Bio's SYNERGY-AI clinical trial matching technology into TOUCH BBCA's digital platform to provide free personalized trial options for Black breast cancer patients and other underrepresented communities. TOUCH BBCA had previously facilitated over 35,000 patient searches before integration; part of Massive Bio's broader strategy to build trusted patient-facing networks that improve equitable access to clinical research.

4Navigating Trials
Strategic tierCore Strategic PartnerTypeGTM or Marketing PartnerAnnounced on2026-05-29
Description

Diversity-focused patient navigation platform launched February 2026; its navigators follow up with patients matched via SYNERGY-AI to guide them through the clinical trial enrollment process. Provides the navigator layer complementing Massive Bio's AI matching for underrepresented communities.

aijourn.com
Strategic tierCore Strategic PartnerTypeStrategic or Co-development PartnerAnnounced on2026-05-14
Description

Strategic partnership combining Just Worldwide's multicultural patient engagement infrastructure with Massive Bio's SYNERGY-AI platform. Just Worldwide leverages fieldwork across North America, Europe, and Asia to raise awareness, onboard patients, and collect medical records that flow through Massive Bio's matching infrastructure. Aims to address clinical trial underenrollment by routing patients through trusted community networks.

Strategic tierFlagship Technology PartnerTypeTechnology or IntegrationAnnounced on2026-04-29
Description

Collaboration to broaden clinical trial access through AI-powered parameterization and pre-screening using OpenAI models. Supports Massive Bio's expansion of global access to clinical trials via integration with OpenAI's generative AI capabilities.

7American Cancer Society (ACS)
Strategic tierFlagship Strategic PartnerTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

Co-developed and powers the ACS ACTS nationwide clinical trial matching program using SYNERGY-AI. Pilot launched Feb 24, 2025 in the Northeast, delivering 900+ trial opportunities and engaging 1,000+ individuals before national expansion to all 50 U.S. states and territories in November 2025. Reduces geographic, financial, and cultural barriers to cancer clinical trial participation.

businesswire.com
Strategic tierCore Strategic PartnerTypeStrategic or Co-development PartnerAnnounced on2025-04-07
Description

Strategic partnership announced April 2025 to expand patient identification capabilities and accelerate clinical trial enrollment across the U.S. Leverages Massive Bio's U.S.-based patient database to identify patients near participating Flatiron research sites who may benefit from trial enrollment, reducing disparities in access and improving outcomes for cancer patients.

Strategic tierCore Strategic PartnerTypeStrategic or Co-development PartnerAnnounced on2024-09-13
Description

Strategic partnership to optimize clinical trial recruitment and expand access to precision cancer care. Combines Massive Bio's digital platform with Foundation Medicine's genomic expertise to increase oncology clinical trial participation through AI-driven patient matching.

Strategic tierCore Technology PartnerTypeTechnology or Integration
Description

Native Oracle Cerner App launch to simplify patient records ingestion and speed up clinical trial matching by integrating directly with Cerner EHR systems.

Strategic tierStrategic PartnerTypeStrategic or Co-development Partner
Description

Strategic partnership announced to expand oncology access by combining Prognos Health's real-world data capabilities with Massive Bio's SYNERGY-AI matching platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Deep 6 AI
TypeDirect peer
Description

AI-driven clinical trial patient matching and site feasibility platform. Directly comparable to Massive Bio's SYNERGY-AI: both sell AI-based patient identification and trial recruitment software to pharma, CROs, and health systems.

2Mendel
TypeDirect peer
Description

AI platform for clinical trial recruitment, real-world data extraction, and patient cohort identification from unstructured medical records. Closely comparable to Massive Bio's oncology trial matching and RWD analytics offerings.

TypeDirect peer
Description

Clinical trial matching and recruitment platform that connects patients and physicians to relevant oncology trials. Direct peer to Massive Bio's patient-facing matching engine, with overlapping pharma/sponsor GTM.

TypeDirect peer
Description

Oncology-focused real-world data and AI platform for trial design, patient identification, and evidence generation. Directly comparable to Massive Bio's NexusPulse and RWD products for oncology sponsors.

TypeDirect peer
Description

Oncology-specific real-world data and EHR platform (Roche-owned) used by sponsors and providers for trial enrollment and evidence. Massive Bio has a formal partnership with Flatiron and competes for the same pharma/CRO RWD and patient identification budgets.

6Tempus
TypeBroad incumbent
Description

Large-scale precision medicine platform combining genomic profiling, AI, and real-world data for oncology and broader indications. Overlaps with Massive Bio on AI-driven trial matching, biomarker intelligence, and pharma RWD, but operates at much broader scale.

TypeBroad incumbent
Description

Global CRO and life sciences technology company offering E360, patient recruitment, real-world evidence, and AI trial design. Massive Bio competes with IQVIA's AI recruitment and RWD products for the same oncology sponsor wallet.

TypeDirect peer
Description

Genomic profiling company (Roche-owned) that powers precision oncology trial enrollment and companion diagnostics. Massive Bio has an active partnership with Foundation Medicine and competes for precision oncology enrollment budgets.

TypeEmerging player
Description

Precision oncology real-world evidence and trial-matching platform serving health systems and life sciences companies. Comparable to Massive Bio on community oncology RWD and pharma RWE partnerships.

TypeOthers
Description

Privacy-preserving / confidential computing AI platform for healthcare and life sciences. Massive Bio is a strategic BeeKeeperAI partner; relevant adjacent technology provider rather than a direct trial-matching competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability15 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance18 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Massive Bio

Oncology Clinical Trial Matching Platformmassivebio.com

Massive Bio operates an AI-powered oncology clinical trial matching platform serving cancer patients, oncologists, and 45 pharma/CRO sponsors across 17 markets, anchored by its SYNERGY-AI engine and Reticulum Nexus multi-agent ecosystem.

What Massive Bio does

Massive Bio, Inc. is a privately held, Delaware-incorporated AI company headquartered in Boca Raton, Florida, founded in 2015. It operates SYNERGY-AI, an oncology-focused clinical trial matching platform that processes more than 500 medical data elements per patient across 19,000+ active oncology and hematology trials in 17 markets. The platform serves three primary customer segments — cancer patients and caregivers (free, self-serve access via multilingual website and iOS/Android apps), referring oncologists and clinical staff (TrialRelay enrollment orchestration), and 45 enterprise pharma and CRO customers (TrialRelay, NexusPulse commercial/medical intelligence, and Real World Data products). A network of 400+ patient advocacy organizations and 130+ strategic partners (including the American Cancer Society, TOUCH BBCA, Flatiron Health, Foundation Medicine, OpenAI, Optellum, Oracle Cerner, and BeeKeeperAI) feeds consented patient flow into the matching pipeline.

The company's underlying technology is a neuro-symbolic, three-agent AI architecture grounded in an oncology-specific knowledge graph, which Massive Bio bundles as the Reticulum Nexus operating system alongside discrete modules such as Patient Connect, TrialRelay (powered by TrialRouter AI), NexusPulse, DrArturo AI, Phoebe AI, and Sentinel Agents. Performance is backed by a peer-reviewed prospective study in ESMO Real World Data and Digital Oncology covering 3,804 cancer patients and 157,000+ clinical documents, which demonstrated 4x faster trial matching than conventional methods, and by a >40% reduction in signal-to-action time from NexusPulse deployments. Massive Bio maintains a broad regulatory and compliance posture spanning HIPAA, GDPR, PIPEDA, LGPD, SOC 2, DiMe Seal 2026, CMS Medicare App Library listing, OHRP FWA (FWA00030601), and EMA Clinical Trial Regulation registration.

The business model is multi-stream: sponsor-supported managed services (pharma/CRO-funded concierge, navigation, and last-mile coordination), enterprise SaaS contracts for patient identification and enrollment acceleration, and licensing of de-identified real-world data and analytics to patient assistance programs, labs, and pharmaceutical manufacturers. The patient-facing service is free, so monetization runs entirely through enterprise and sponsor channels. To date, Massive Bio has raised approximately $23.3M in cumulative disclosed funding across multiple rounds through a $16.5M Series B led by Revo Capital in December 2022, and the company remains founder-led by CEO Selin Kurnaz, PhD, Chief Medical AI Officer Arturo Loaiza-Bonilla, MD, MSEd, FACP, and CTO/COO Çağatay M. Çulcuoğlu.

Massive Bio firmographics

Firmographics
Name
Massive Bio
Legal name
Massive Bio Inc.
Website
https://massivebio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
Massive Bio operates an AI-powered oncology clinical trial matching platform serving cancer patients, oncologists, and 45 pharma/CRO sponsors across 17 markets, anchored by its SYNERGY-AI engine and Reticulum Nexus multi-agent ecosystem.
Ownership category
akta.pro rank

Massive Bio industry classification

Industry
Product category
Oncology Clinical Trial Matching Platform
NAICS
Computer Systems Design and Related Services (54151), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Prepackaged Software (7372), Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAE
Clinical Decision Support & Workflow Integration (EHR/oncology systems)
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination

Keywords

  • Clinical trial matching
  • Oncology patient recruitment
  • AI clinical trials
  • Real-world data analytics
  • Patient navigation services

Where Massive Bio is headquartered

Location

Headquarters

HQ city
Boca Raton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Massive Bio business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Personnel, Technology or R&D

Revenue model

  1. Sponsor-Supported Services: Clinical trial sponsors (pharmaceutical or biotechnology companies) fund concierge, navigation, and last-mile coordination services via payments made directly to Massive Bio. Funding does not affect patient rights, cost of care, or eligibility, and is disclosed transparently in patient-facing consents. Identifiable patient data is not shared with sponsors — only de-identified aggregate study metrics.
  2. Enterprise SaaS — Pharma / CRO Patient Identification and Trial Enrollment: B2B contracts with 45 pharma and CRO customers (per company) for patient identification, trial enrollment acceleration, site identification, and Real World Data analytics, including TrialRelay™ enrollment orchestration and NexusPulse™ commercial/medical intelligence.
  3. De-Identified Real-World Data and Analytics Licensing: Massive Bio uses Non-PII to consult other users and may share, lease, or sell de-identified data and analysis to patient assistance programs, clinical laboratories, cancer screening providers, pharmaceutical manufacturers, and oncologists for improvement of professional services and to educate the public.
  4. Patient-Facing Service (Free to Patients): Cancer patients and caregivers receive clinical trial matching, second-opinion reports, and patient navigation at no cost; revenue is captured indirectly through sponsor and enterprise contracts rather than direct patient fees.

Pricing tiers

ModelBillingPrice
Freemium—Free patient-facing service
Other—Quote-based sponsor / pharma / CRO enterprise services

Go-to-market motion5 records

Distribution channels7 records

Marketing channels9 records

Massive Bio product offering

Product offering

Core offering

Massive Bio operates an AI-powered oncology clinical trial matching platform (SYNERGY-AI) wrapped in the Reticulum Nexus multi-agent operating system, processing 500+ medical data elements per patient against 19,000+ active oncology and hematology trials across 17 markets and 11 languages to deliver physician-reviewed trial reports within 24 hours. It sells TrialRelay physician-facing enrollment orchestration, NexusPulse real-time AI commercial/medical intelligence, and de-identified Real World Data products to pharmaceutical companies, CROs, health systems, and patient advocacy organizations, while offering free clinical trial matching, navigation, and educational content to cancer patients and caregivers.

Product overview

Massive Bio offers a single unified AI-powered oncology intelligence platform anchored by its flagship SYNERGY-AI™ clinical trial matching engine, wrapped in the next-generation Reticulum Nexus™ multi-agent operating system that orchestrates the full oncology patient journey. The Reticulum Nexus™ suite integrates discrete modules — Patient Connect™ (patient-facing navigation), TrialRelay™ (physician-facing enrollment orchestration) powered by TrialRouter™ AI, NexusPulse™ (real-time AI signal engine for oncology markets), NexusPulse™ Intelligent Calculators, and AI agents Sentinel Agents™, DrArturo AI™, and Phoebe AI™ — into one real-time system. The platform's neuro-symbolic, three-agent AI architecture is grounded in an oncology-specific knowledge graph and validated across 3,804 patients with four-times-faster matching than conventional methods. Supporting products include mobile apps (Synergy-AI Clinical Trial Finder and Cancer Quiz), an Oracle Cerner EHR-integrated app, complementary services (Clinical Trial Matching, Virtual Tumor Board, Drug Utilization Optimizer (DUO), Real World Data), and the Little Tales for Massive Heroes pediatric storybook.

Differentiator

Problem solved

Functional benefit

Brands

  • SYNERGY-AI: Massive Bio's AI-powered clinical trial matching platform used to match cancer patients with oncology and hematology clinical trials.
  • Reticulum Nexus
  • TrialRelay
  • NexusPulse
  • Patient Connect
  • TrialRouter
  • DrArturo AI
  • Phoebe AI
  • Sentinel Agents

Products and services

  • SYNERGY-AI Clinical Trial Matching Platform AI-powered clinical trial matching platform that processes 500+ medical data elements per patient against 19,000+ active oncology and hematology trials, delivering personalized physician-reviewed trial reports within 24 hours to cancer patients, oncologists, and sponsors across 17 markets. Validated across 3,804 cancer patients and 157,000+ clinical documents.
  • Reticulum Nexus Product Suite AI-powered multi-agent oncology intelligence ecosystem and operating system for oncology access. Orchestrates patient engagement, medical records, eligibility interpretation, clinical trial pre-screening, physician referral orchestration, biomarker intelligence, site activation, and patient navigation into a single real-time AI-enabled operating layer for patients, physicians, sponsors, and CROs.
  • TrialRelay Physician-facing AI-powered enrollment orchestration platform powered by TrialRouter AI that eliminates 'referral black holes' by providing warm handoffs, continuous visibility, and closed-loop accountability for oncology patient referrals across health systems and external institutions. Sold to oncologists, health systems, and pharma/CRO sponsors.
  • NexusPulse Real-time AI signal engine for oncology markets that transforms consented real-world clinical and biomarker data into actionable commercial, medical, and market access intelligence for pharma and CRO customers. Built within the Reticulum Nexus ecosystem.
  • Patient Connect Patient-facing trial navigation tool that empowers cancer patients and caregivers to manage and navigate their clinical trial journey anytime, anywhere, all in one place. Free to patients; bundled within the Reticulum Nexus ecosystem.
  • Virtual Tumor Board Online service providing remote access to bioinformatics and molecular expertise to support patient presentations at tumor boards for oncologists and care teams.
  • Drug Utilization Optimizer (DUO)

Quantifiable outcome

  • 4x faster AI-driven trial matching vs. conventional methods, validated across 3,804 cancer patients and 157,000+ clinical documents (peer-reviewed in ESMO Real World Data and Digital Oncology)
  • +6 more outcomes

Companies that use Massive Bio

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Massive Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability15 records

Feature10 records

Massive Bio partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered flagship strategic partner, core technology partner, core strategic partner, flagship technology partner and strategic partner.

  • Optellumflagship strategic partnerStrategic or Co-development Partner · 3 June 2026Strategic collaboration announced June 2026 to connect AI-powered lung cancer detection with clinical trial matching for early-stage NSCLC patients. Optellum's FDA-cleared Lung Cancer Prediction (LCP) AI identifies high-risk patients from CT imaging; de-identified data is processed by Massive Bio's platform to match them with geographically accessible NSCLC clinical trials. Targets the gap where most high-risk patients never reach trials despite early detection raising 5-year survival from 9% to 64%.
  • BeeKeeperAIcore technology partnerTechnology or Integration · 30 May 2026Collaboration enabling privacy-preserving AI-powered clinical trial matching in oncology through encrypted computing, allowing AI models to run on sensitive patient data without exposing it.
  • TOUCH, The Black Breast Cancer Alliance (BBCA)core strategic partnerGTM or Marketing Partner · 29 May 2026Embeds Massive Bio's SYNERGY-AI clinical trial matching technology into TOUCH BBCA's digital platform to provide free personalized trial options for Black breast cancer patients and other underrepresented communities. TOUCH BBCA had previously facilitated over 35,000 patient searches before integration; part of Massive Bio's broader strategy to build trusted patient-facing networks that improve equitable access to clinical research.
  • Navigating Trialscore strategic partnerGTM or Marketing Partner · 29 May 2026Diversity-focused patient navigation platform launched February 2026; its navigators follow up with patients matched via SYNERGY-AI to guide them through the clinical trial enrollment process. Provides the navigator layer complementing Massive Bio's AI matching for underrepresented communities.
  • Just Worldwidecore strategic partnerStrategic or Co-development Partner · 14 May 2026Strategic partnership combining Just Worldwide's multicultural patient engagement infrastructure with Massive Bio's SYNERGY-AI platform. Just Worldwide leverages fieldwork across North America, Europe, and Asia to raise awareness, onboard patients, and collect medical records that flow through Massive Bio's matching infrastructure. Aims to address clinical trial underenrollment by routing patients through trusted community networks.
  • OpenAIflagship technology partnerTechnology or Integration · 29 April 2026Collaboration to broaden clinical trial access through AI-powered parameterization and pre-screening using OpenAI models. Supports Massive Bio's expansion of global access to clinical trials via integration with OpenAI's generative AI capabilities.
  • American Cancer Society (ACS)flagship strategic partnerStrategic or Co-development Partner · 18 November 2025Co-developed and powers the ACS ACTS nationwide clinical trial matching program using SYNERGY-AI. Pilot launched Feb 24, 2025 in the Northeast, delivering 900+ trial opportunities and engaging 1,000+ individuals before national expansion to all 50 U.S. states and territories in November 2025. Reduces geographic, financial, and cultural barriers to cancer clinical trial participation.
  • Flatiron Healthcore strategic partnerStrategic or Co-development Partner · 7 April 2025Strategic partnership announced April 2025 to expand patient identification capabilities and accelerate clinical trial enrollment across the U.S. Leverages Massive Bio's U.S.-based patient database to identify patients near participating Flatiron research sites who may benefit from trial enrollment, reducing disparities in access and improving outcomes for cancer patients.
  • Foundation Medicinecore strategic partnerStrategic or Co-development Partner · 13 September 2024Strategic partnership to optimize clinical trial recruitment and expand access to precision cancer care. Combines Massive Bio's digital platform with Foundation Medicine's genomic expertise to increase oncology clinical trial participation through AI-driven patient matching.
  • Oracle Cernercore technology partnerTechnology or IntegrationNative Oracle Cerner App launch to simplify patient records ingestion and speed up clinical trial matching by integrating directly with Cerner EHR systems.
  • Prognos Healthstrategic partnerStrategic or Co-development PartnerStrategic partnership announced to expand oncology access by combining Prognos Health's real-world data capabilities with Massive Bio's SYNERGY-AI matching platform.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Massive Bio competitors and assessment

Company assessment

Direct peers

  • Deep 6 AI: AI-driven clinical trial patient matching and site feasibility platform. Directly comparable to Massive Bio's SYNERGY-AI: both sell AI-based patient identification and trial recruitment software to pharma, CROs, and health systems.
  • Mendel: AI platform for clinical trial recruitment, real-world data extraction, and patient cohort identification from unstructured medical records. Closely comparable to Massive Bio's oncology trial matching and RWD analytics offerings.
  • Trial Library: Clinical trial matching and recruitment platform that connects patients and physicians to relevant oncology trials. Direct peer to Massive Bio's patient-facing matching engine, with overlapping pharma/sponsor GTM.
  • ConcertAI: Oncology-focused real-world data and AI platform for trial design, patient identification, and evidence generation. Directly comparable to Massive Bio's NexusPulse and RWD products for oncology sponsors.
  • Flatiron Health: Oncology-specific real-world data and EHR platform (Roche-owned) used by sponsors and providers for trial enrollment and evidence. Massive Bio has a formal partnership with Flatiron and competes for the same pharma/CRO RWD and patient identification budgets.
  • Foundation Medicine: Genomic profiling company (Roche-owned) that powers precision oncology trial enrollment and companion diagnostics. Massive Bio has an active partnership with Foundation Medicine and competes for precision oncology enrollment budgets.

Broad incumbents

  • Tempus: Large-scale precision medicine platform combining genomic profiling, AI, and real-world data for oncology and broader indications. Overlaps with Massive Bio on AI-driven trial matching, biomarker intelligence, and pharma RWD, but operates at much broader scale.
  • IQVIA: Global CRO and life sciences technology company offering E360, patient recruitment, real-world evidence, and AI trial design. Massive Bio competes with IQVIA's AI recruitment and RWD products for the same oncology sponsor wallet.

Emerging players

  • Syapse: Precision oncology real-world evidence and trial-matching platform serving health systems and life sciences companies. Comparable to Massive Bio on community oncology RWD and pharma RWE partnerships.

Others

  • BeeKeeperAI: Privacy-preserving / confidential computing AI platform for healthcare and life sciences. Massive Bio is a strategic BeeKeeperAI partner; relevant adjacent technology provider rather than a direct trial-matching competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights8 records

Customer concentration

Massive Bio social profiles

Digital presence

Massive Bio compliance and trust

Trust signal

Compliance18 records

Massive Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Massive Bio leadership team

Management profile

Number of profiles

Profiles3 records

Massive Bio funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Massive Bio M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Massive Bio

What does Massive Bio do?

Massive Bio operates an AI-powered oncology clinical trial matching platform (SYNERGY-AI) wrapped in the Reticulum Nexus multi-agent operating system, processing 500+ medical data elements per patient against 19,000+ active oncology and hematology trials across 17 markets and 11 languages to deliver physician-reviewed trial reports within 24 hours. It sells TrialRelay physician-facing enrollment orchestration, NexusPulse real-time AI commercial/medical intelligence, and de-identified Real World Data products to pharmaceutical companies, CROs, health systems, and patient advocacy organizations, while offering free clinical trial matching, navigation, and educational content to cancer patients and caregivers.

Is Massive Bio a public or private company?

Massive Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Massive Bio founded?

Massive Bio was founded in 2019. It employs 101 to 250 people.

Where is Massive Bio based?

Massive Bio is headquartered in Boca Raton, United States, in the North America region.

How does Massive Bio make money?

Four revenue lines are on record. Sponsor-Supported Services are the primary driver. The others are enterprise SaaS — Pharma / CRO Patient Identification and Trial Enrollment, de-Identified Real-World Data and Analytics Licensing and patient-Facing Service (Free to Patients).

Who are Massive Bio's main competitors?

Direct peers on record are Deep 6 AI, Mendel, Trial Library, ConcertAI, Flatiron Health and Foundation Medicine. Broad incumbents are Tempus and IQVIA. Syapse is listed as an emerging player. BeeKeeperAI is listed as an others.

Does Massive Bio have an API?

No public API is recorded for Massive Bio.

What industry is Massive Bio in?

Massive Bio's product category is Oncology Clinical Trial Matching Platform. Its primary akta.pro industry code is HLAAANAI, Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials), with a secondary code of HLAGAJAF, Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D). Its NAICS code is 54151 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireMassive Bio and Global Leadership in Oncology & Wellness (GLOW) Announce Partnership to Expand Clinical Trial AccessMassive Bio and GLOW Oncology announced a partnership to connect patients and caregivers with clinical trial matching and navigation support. The collaboration combines GLOW's community programs with Massive Bio's AI-powered trial matching platform. Both organizations aim to improve access to clinical trials for cancer patients.Business Wire BlogMassive Bio and Global Leadership in Oncology & Wellness (GLOW) Announce Partnership to Expand Access to Clinical Trial Information for Patients and CaregiversMassive Bio and GLOW announced a partnership to connect patients and caregivers with clinical trial matching and navigation support. The collaboration pairs GLOW's community programs with Massive Bio's AI-powered platform, aiming to expand access to trial information.EIN PresswireMassive Bio and Global Leadership in Oncology & Wellness (GLOW) Announce Partnership to Expand Clinical Trial AccessMassive Bio and GLOW Oncology announced a partnership to connect patients and caregivers with clinical trial matching and navigation support. The collaboration combines GLOW's community programs with Massive Bio's AI-powered trial matching platform. Both organizations aim to improve access to clinical trials for cancer patients.FinancialContent Business PageMassive Bio and Global Leadership in Oncology & Wellness (GLOW) Announce Partnership to Expand Access to Clinical Trial Information for Patients and CaregiversMassive Bio and GLOW announced a partnership to connect patients and caregivers with clinical trial matching and navigation support. The collaboration pairs GLOW's community programs with Massive Bio's AI-powered platform, aiming to help families make informed decisions about cancer care.EIN PresswireTIME Recognizes Massive Bio Among the Top HealthTech Companies in AI and Data AnalyticsMassive Bio was named among TIME's Top HealthTech Companies 2026 in AI and Data Analytics. The company's RNex multi-agent AI platform connects patient-consented data with oncology drug development, and it has onboarded over 200,000 cancer patients across 17 countries.EIN PresswireUS healthtech company Massive Bio expands Asia footprint with South Korea market pushMassive Bio appointed Intralink to support its expansion into South Korea's oncology sector, with the Seoul team building relationships with hospitals, labs, and oncologists. The company has matched 200,000 patients with 19,000 clinical trials across 17 markets. It will also attend the 2026 AACR-KCA Joint Conference in November.Business Wire BlogUS Healthtech Company Massive Bio Expands Asia Footprint With South Korea Market PushMassive Bio appointed Intralink to support its expansion into South Korea's oncology sector, building partnerships with hospitals, labs, and oncologists. The company's AI platform has matched 200,000 patients with 19,000 clinical trials across 17 markets. Intralink's Seoul team will engage the Korean oncology community, including at the 2026 AACR-KCA conference.EIN PresswireMassive Bio and PrecisCa Announce Strategic Partnership to Expand Cancer Patient Access to Clinical Trials Across the USMassive Bio and PrecisCa announced a strategic partnership to expand cancer patient access to clinical trials across the U.S. Massive Bio will provide concierge support and referral coordination, while PrecisCa contributes prescreening and matching services to its oncology provider network. The companies expect to begin integrating patient surfacing workflows in the coming months.Business Wire BlogMassive Bio and PrecisCa Announce Strategic Partnership to Expand Cancer Patient Access to Clinical Trials Across the U.S.Massive Bio and PrecisCa announced a strategic partnership to expand cancer patient access to clinical trials across the U.S. Massive Bio will provide concierge support and referral coordination, while PrecisCa contributes prescreening and trial matching services to its oncology provider network. The companies expect to begin integrating patient surfacing workflows in the coming months.MorningstarMy Adult Doctor™ Launches Nationwide Virtual Healthcare Platform Expanding 24/7 Urgent Care, Primary Care, Wellness, and Advanced Digital and AI Health Services Across All 50 States, Puerto Rico, andQC Healthcare launched My Adult Doctor, a nationwide virtual healthcare platform offering 24/7 urgent care, primary care, wellness, and AI-enabled services across all 50 states, Puerto Rico, and Guam. The platform includes GLP-1 and peptide therapies and partners with Massive Bio to expand oncology clinical trial access.